NCT02684617 2021-03-01
KEYNOTE-155
Merck Sharp & Dohme LLC
Phase 1 Terminated
Clinical Trials
7 trialsNCT00871910 2017-10-23
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01580228 2017-02-23
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00871546 2015-08-07
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00871663 2015-04-20
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01650727 2015-02-10
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00798213 2015-02-04
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 2 Terminated